PIK3R1 Mutations Cause Syndromic Insulin Resistance with Lipoatrophy  by Thauvin-Robinet, Christel et al.
REPORT
PIK3R1 Mutations Cause Syndromic
Insulin Resistance with Lipoatrophy
Christel Thauvin-Robinet,1,2,25,* Martine Auclair,3,4,5,25 Laurence Duplomb,1,25
Martine Caron-Debarle,3,4,5 Magali Avila,1 Judith St-Onge,1,6 Martine Le Merrer,7 Bernard Le Luyer,8
Delphine He´ron,9 Miche`le Mathieu-Dramard,10 Pierre Bitoun,11 Jean-Michel Petit,12 Sylvie Odent,13,14
Jeanne Amiel,4 Damien Picot,1 Virginie Carmignac,1 Julien Thevenon,1,2 Patrick Callier,1,15
Martine Laville,16,17 Yves Reznik,18,19,20 Ce´dric Fagour,21 Marie-Laure Nunes,21 Jacqueline Capeau,3,4,5,22
Olivier Lascols,3,4,5,23 Fre´de´ric Huet,1,24 Laurence Faivre,1,2 Corinne Vigouroux,3,4,5,22
and Jean-Baptiste Rivie`re1,6,*
Short stature, hyperextensibility of joints and/or inguinal hernia, ocular depression, Rieger anomaly, and teething delay (SHORT) syn-
drome is a developmental disorder with an unknown genetic cause and hallmarks that include insulin resistance and lack of subcutane-
ous fat.We ascertained two unrelated individuals with SHORTsyndrome, hypothesized that the observed phenotypewasmost likely due
to de novo mutations in the same gene, and performed whole-exome sequencing in the two probands and their unaffected parents. We
then confirmed our initial observations in four other subjects with SHORT syndrome from three families, as well as 14 unrelated subjects
presenting with syndromic insulin resistance and/or generalized lipoatrophy associated with dysmorphic features and growth retarda-
tion. Overall, we identified in nine affected individuals from eight families de novo or inherited PIK3R1 mutations, including a muta-
tional hotspot (c.1945C>T [p.Arg649Trp]) present in four families. PIK3R1 encodes the p85a, p55a, and p50a regulatory subunits of class
IA phosphatidylinositol 3 kinases (PI3Ks), which are known to play a key role in insulin signaling. Functional data from fibroblasts
derived from individuals with PIK3R1 mutations showed severe insulin resistance for both proximal and distal PI3K-dependent
signaling. Our findings extend the genetic causes of severe insulin-resistance syndromes and provide important information with
respect to the function of PIK3R1 in normal development and its role in human diseases, including growth delay, Rieger anomaly
and other ocular affections, insulin resistance, diabetes, paucity of fat, and ovarian cysts.Insulin resistance is closely associated with many com-
mon, complex, and multifactorial conditions, including
obesity, type 2 diabetes, atherosclerosis, nonalcoholic
fatty-liver disease, and polycystic-ovary syndrome. Rare
monogenic forms of insulin resistance also exist, and iden-
tifying the genetic basis of such phenotypes provides
unique opportunities for deciphering the multiple molec-
ular mechanisms leading to insulin resistance.1 SHORT
syndrome (MIM 269880)—whose acronym stands for
short stature, hyperextensibility of joints and/or inguinal
hernia, ocular depression, Rieger anomaly, and teething
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Vertical and male-to-male transmission have been
described, indicative of autosomal-dominant inheri-
tance.2 Mutations in PITX2 (MIM 601542) and BMP4
(MIM 112262) have been discussed as putatively causative,
but no mutations were identified in subjects with typical
SHORT syndrome.3,4
We ascertained two unrelated individuals with a strik-
ingly similar clinical presentation consistent with SHORT
syndrome (Table 1 and Figures 1A–1D). Given the absence
of recurrence of the syndrome in both families, we hypoth-
esized that the observed phenotype was most likely due to
de novomutations in the same gene and performedwhole-
exome sequencing in the two probands and their unaf-
fected parents. We then confirmed our initial observations
in four other subjects with SHORT syndrome from three
families, as well as 14 unrelated subjects presenting with
syndromic insulin resistance and/or generalized lipoatro-
phy associated with dysmorphic features and growth retar-
dation. Written, informed consent was obtained from all
subjects, legal representatives, and relatives before enroll-
ment in the study. The research protocol was approved
by the ethics committees at participating institutions. Indi-
viduals were diagnosed with SHORT syndrome on the basis
of previously reported clinical features.2
For all study subjects, genomic DNA was extracted from
blood according to standard procedures. Whole-exome
capture and sequencing were performed from 5 mg of
genomic DNA at the PerkinElmer DNA Sequencing Service.
Exome capture was performed with the 51 Mb SureSelect
Human All Exon V4 kit (Agilent). Generated libraries
were sequenced on a HiSeq 2000 (Illumina) according
to the manufacturer’s recommendations for paired-end
100 bp reads. We generated over 4 Gb of mappable
sequence per individual, resulting in a depth of coverage
of at least ten reads for more than 85% of the targeted
exome (Table S1, available online). Sequencing data were
processed as previously described.5,6 Raw single-nucleotide
variants (SNVs) and indels were identified with the
Genome Analysis Toolkit (GATK v.2.1-10)7 Unified Geno-
typer tool with a variant quality score R 30. Variants
were then filtered with the GATK Variant Filtration tool
and the following hard-filtering expressions: ‘‘QD < 2.0,’’
‘‘ReadPosRankSum<8.0,’’ and ‘‘FS > 200.0.’’ Filtered var-
iants were annotated with SeattleSeq SNP Annotation (see
Web Resources). As previously described,6 we systemati-
cally identified candidate de novo events by focusing on
protein-altering and splice-site DNA changes (1) absent
in the National Heart, Lung, and Blood Institute (NHLBI)
Exome Sequencing Project Exome Variant Server (EVS;
see Web Resources), (2) supported by at least two reads
and R20% of total reads in the proband, and (3) absent
in both parents (two variant reads or fewer and %5% of
total reads) at base-pair positions covered by at least
four reads in the entire trio. Candidate de novo changes
were then manually inspected with the Integrative
Genomics Viewer.8 This analysis identified de novo muta-
tions in PIK3R1 (MIM 171833, RefSeq accession number142 The American Journal of Human Genetics 93, 141–149, July 11, 2NM_181523.2) in both affected individuals, P1
(c.1615_1617delATT [p.Ile539del]) and P2 (c.1465G>A
[p.Glu489Lys]) ( Table S2). Both mutations were confirmed
as de novo by standard PCR protocols with the use of
custom intronic primers combined with capillary
sequencing. PIK3R1 encodes the p85a, p55a, and p50a
regulatory subunits of class IA phosphatidylinositol 3
kinases (PI3Ks), which are dimers composed of a p110 cat-
alytic subunit and a p85 regulatory subunit. PI3K signaling
is involved in multiple cellular functions, such as cell
growth, proliferation, migration, metabolism, angiogen-
esis, survival, and apoptosis, and mutations in several of
the core components of the PI3K pathway have been asso-
ciated with some of the most prevalent human diseases,
including diabetes and cancer.9
We screened PIK3R1 for mutations in four individuals
with SHORT syndrome from three additional families.
The coding and flanking intronic regions of PIK3R1
(RefSeq NM_181523.2, NM_181524.1, and NM_
181504.3) were amplified by standard PCR protocols
(primer sequences are available upon request). Sequencing
was performed with the ABI BigDye Terminator Cycle
Sequencing kit (v.3.1) and an ABI 3130 Genetic Analyzer
(Applied Biosystems) according to the manufacturer’s in-
structions. Sequence traces were analyzed with Mutation
Surveyor (v.4.0.7, SoftGenetics). This experiment identi-
fied a recurrent substitution (c.1945C>T [p.Arg649Trp])
in all four subjects (Table 2), and it proved to be de novo
in the only simplex case for which parental DNA was
available (P3, who was previously reported;10 Figure 1E).
The remaining three individuals with PIK3R1 mutations
included a simplex case (P4) and an affected woman and
her terminated fetus (P5 [II-5 in Figure 1F] and P6 [III-2
in Figure 1F], Figures 1F–1H). The c.1945C>T mutation
occurs within the context of a CpG dinucleotide, which
might explain its recurrence. We then sequenced PIK3R1
in a heterogeneous clinical group of 14 additional unre-
lated subjects presenting with severe insulin resistance
and/or generalized lipoatrophy associated with dysmor-
phic features and growth retardation (Table S3). None of
these cases had been previously diagnosed with SHORT
syndrome, and none had mutations in AGPAT2 (MIM
603100), BSCL2 (MIM 606158), LMNA (MIM 150330),
PPARG (MIM 601487), or INSR (MIM 147670). Capillary
sequencing identified mutations in three of these
subjects: the previously identified recurrent substitution
(c.1945C>T [p.Arg649Trp]) in P7, a single-nucleotide
insertion predicted to result in a prematurely truncated
protein (c.1943dupT [p.Arg649Profs*5]) in P8, and a substi-
tution (c.1892G>A [p.Arg631Gln]) in P9 (Table 2).
Although all three individuals had facial dysmorphism
retrospectively consistent with SHORT syndrome, the
limited available clinical data did not allow confirmation
of the clinical diagnosis of SHORT syndrome (Table 1).
Nucleotide-level conservation and the impact of amino
acid substitutions were assessed with Genomic Evolu-
tionary Rate Profiling (GERP),11 Grantham matrix,12 and013
Table 1. Clinical Features of Individuals with Mutations in PIK3R1
Individual
P1 P2 P3a P4 P5 P6 P7 P8 P9
Sex male male female male female male female female male
Features of SHORT Syndrome Acronym
Measurements at birth
Gestational age 34 weeks of gestation þ
4 days
34 weeks of gestation 35.5 weeks of
gestation
35 weeks of
gestation
term 27 weeks of
gestation
term ND prematurity
Length (cm) 42 (<3rd per) 40 (<3rd per) 43.5 (<3rd per) 47 (25th per) 52 (20th per) 40 (50th per) NA NA NA
Weight (g) 1,460 (<3rd per) 1,380 (<3rd per) 1,830 (<3rd per) 2,000 (3rd per) 2,260 (<3rd per) 1,400 (50th per) 2,700 (3rd per) ND 950
OFC (cm) 29.5 (3rd per) 28.5 (<3rd per) 32 (20th per) 33 (40th per) unknown 25 (10th per) ND ND ND
Measurements at last follow-up examination
Age 7 years and 7 months 7 years and 8 months 19 years 20 months 40 years ND 28 years 60 years 28 years
Length (cm) 109.7 (<3rd per) 111.8 (<3rd per) 146.5 (<3rd per) 80.5 (40th per) 160 (25th per) ND 145 (<3rd per) 143 (<3rd per) 155 (<3rd per)
Weight (kg) 15 (<3rd per) 15.5 (<3rd per) 36 (<3rd per) 8.76 (<3rd per) 50 (<3rd per) ND 44.6 (<3rd per) 35 (<3rd per) 42 (<3rd per)
OFC (cm) 47 (<3rd per) 47 (<3rd per) unknown 47 (20th per) 51 (<3rd per) ND ND ND ND
BMI 12.5 (<3rd per) 12.4 (<3rd per) 16.8 (<3rd per) 13.5 (<3rd per) 19.5 (35th per) ND 21.2 (25th per) 17.1 (3rd per) 17.5 (3rd per)
Hyperextensibility of joints   þ  þ  ND ND ND
Inguinal hernia      ND   
Ocular depression þ þ þ þ þ þ ND þ 
Rieger anomaly   þ  þ ND   
Teeth delay þ þ þ þb þ ND þ ND ND
Number of features of acronym 3/5 3/5 5/5 2/5 4/5 1/3 2/3 2/3 1/3
Other Findings
Ophthalmological findings
Hyperopia þ þ þ þ  ND ND ND ND
Astigmatism þ  þ   ND þ ND ND
Myopia     þ ND ND ND ND
Esotropia   þ   ND ND ND ND
Lack of subcutaneous fat þ þ þ þ þ ND þ þ þ
Insulin resistance þ þ þ ND þ ND þ þ þ
Diabetes   þ  þ ND þ þ þ
(Continued on next page)
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Table 1. Continued
Individual
P1 P2 P3a P4 P5 P6 P7 P8 P9
Facial dysmorphim
Triangular shape þ þ þ þ þ þ ND þ þ
Prominent forehead þ þ þ þ þ þ þ þ 
Hypoplastic or thin alae nasi þ þ þ þ þ þ þ þ þ
Small chin þ þ þ þ þ þ þ þ þ
Large low-set ears þ þ þ þ þ þ þ þ þ
Mild midface hypoplasia þ þ þ þ þ þ ND þ 
Micrognathia þ þ þ þ þ þ þ þ þ
Thin, wrinkled skin þ þ  þ  ND þ þ ND
Readily visible veins þ þ  þ  ND þ þ ND
Frequent illnesses     þ ND ND þ ND
Ovarian cysts NA NA þ NA þ NA þ ND NA
Mental development
Normal    þ þ ND þ þ 
Mild impairment and/or speech delay þ þ þ   ND   þ
Radiographic findings
Delayed bone age þ þ þ ND ND ND ND ND ND
Gracile long bones   þ ND ND ND ND ND ND
Abbreviations are as follows: per, percentile; þ, presence of a feature; , absence of a feature; OFC, occipitofrontal circumference; BMI, body mass index; NA, not applicable; and ND, no data.
aSubject previously reported.
bNo teeth at last follow-up examination.
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Figure 1. Appearance of Individuals with SHORT Syndrome, Test Results for Oral Glucose Tolerance, and Distribution of PIK3R1
Mutations
(A–H) Photos of subjects P1 (A–C), P2 (D), and P3 (E) and familial pedigree and photos of subject P5 (F–H). Subjects presented with a
typical triangular facial shape, deep-set eyes, thin and hypoplastic alae nasi, a small chin, mild midfacial hypoplasia, and lipoatrophy.
We obtained written consent to publish photographs of the subjects.
(I) Test results for oral glucose tolerance show hyperglycemia in subjects P3 (at 13.5 years of age) and P7 and increased serum insulin
levels in all affected children (subjects P1, P2, and P3).
(J) Schematic representation of the three isoforms encoded by PIK3R1, their functional domains, and the alterations identified in indi-
viduals with SHORT syndrome.PolyPhen-2 (with the HumVar-trained model)13 scores.
In addition to the fact that three of the identified
missense PIK3R1 mutation sites (encoding p.Ile539del,
p.Glu489Lys, and p.Arg649Trp) were found to be de
novo in one subject each, all mutation sites affect highly
conserved nucleotides and are predicted to be possibly or
probably damaging (Table 2). None of the five mutation
sites were reported in the NHLBI EVS (Table S4), which
consists of whole-exome-sequencing data from ~6,500 in-
dividuals (the EVS was accessed March 2013), dbSNP137
(see Web Resources), or the 1000 Genomes Project (see
Web Resources). A single truncating mutation (c.901C>T
[p.Arg301*]), which was present in a heterozygous state
in a single individual, was reported in the EVS data set.
Contrary to the truncating mutation identified in the
present study and predicted to affect all three subunits
encoded by PIK3R1 (i.e., p85a, p55a, and p50a), the muta-The Amtion encoding p.Arg301* is predicted to affect only the
p85a subunit. We can speculate that disruption of all three
PIK3R1 subunits is required for the development of SHORT
syndrome, which is consistent with a recent report of a
complete loss of p85a (but normal p55a and p50a expres-
sion) in an individual with absent B cells but normal
growth, development, and fasting glucose and insulin
levels.14
Class IA PI3Ks play a key role in insulin signaling
through binding of phosphorylated insulin-receptor
substrates, production of phosphatidylinositol-4,5-tri-
sphosphate (PIP3), and subsequent activation of AKT
serine-threonine kinase.15 A test for oral glucose tolerance
was performed according to the recommended proce-
dures16 and showed increased insulin levels in the three
affected children tested (subjects P1, P2, and P3 [Figure 1I
and Table S5]). Subjects P3 and P7 developed diabetes aterican Journal of Human Genetics 93, 141–149, July 11, 2013 145
Table 2. Summary of PIK3R1 Mutations Identified in Nine Affected Individuals from Eight Families
Individual
Mutation
Coordinates
(hg19)
Alleles
(Ref/Alt) cDNA Change
Amino Acid
Change
Grantham
Score
GERP
Score PolyPhen-2 Inheritance
P1 chr5: 67,591,018 AATT/A c.1615_1617delATT p.Ile539del - - - de novo
P2 chr5: 67,590,403 G/A c.1465G>A p.Glu489Lys 56 5.07 possibly damaging (0.67) de novo
P3 chr5: 67,592,129 C/T c.1945C>T p.Arg649Trp 101 5.15 probably damaging (1.00) de novo
P4 chr5: 67,592,129 C/T c.1945C>T p.Arg649Trp 101 5.15 probably damaging (1.00) absent in mother,
father not available
P5 chr5: 67,592,129 C/T c.1945C>T p.Arg649Trp 101 5.15 probably damaging (1.00) absent in mother,
father not available
P6 chr5: 67,592,129 C/T c.1945C>T p.Arg649Trp 101 5.15 probably damaging (1.00) inherited from
mother (p5)
P7 chr5: 67,592,129 C/T c.1945C>T p.Arg649Trp 101 5.15 probably damaging (1.00) parents not available
P8 chr5: 67,592,127 T/TT c.1943dupT p.Arg649Profs*5 - - - parents not available
P9 chr5: 67,592,076 G/A c.1892G>A p.Arg631Gln 43 5.15 probably damaging (0.94) parents not available
Mutation nomenclature is based on RefSeq accession number NM_181523.2. Abbreviations are as follows: Ref, reference allele; alt, alternative allele; and GERP,
Genomic Evolutionary Rate Profiling.13.5 and 12 years of age, respectively, which explains
their hyperglycemia and why their levels of serum insulin
were lower than those of other affected individuals.
Interestingly, in contrast to other monogenic forms of
insulin resistance and lipodystrophy, SHORT syndrome
resulting from mutations in PIK3R1 is not associated
with severe hypertriglyceridemia (Table S5). Multiple lines
of evidence indicate that the PIK3R1 mutations identified
here should result in decreased PI3K activity. In humans,
loss of insulin receptor (INSR) causes Donohue (MIM
246200) and Rabson-Mendenhall (MIM 262190) syn-
dromes, both of which share many features with SHORT
syndrome, including growth restriction, extreme insulin
resistance, paucity of body fat, dysmorphic features,
inguinal hernia, wrinkled skin, ovarian cysts, and/or
dysplastic teeth.17 Mice carrying a heterozygous mutation
abrogating p110a kinase activity display small body size,
insulin resistance, and glucose intolerance.18 Interestingly,
loss of AKT2 function is associated with severe insulin
resistance, diabetes, and lipoatrophy in humans and
mice,19,20 but unlike in SHORT syndrome, hypertriglyceri-
demia and increased de novo lipogenesis are part of
the phenotype.21 Conversely, mutations in several PI3K-
AKT-pathway-related genes result in increased PI3K
signaling and cause severe brain and/or body over-
growth,5 and an activating mutation in AKT2 in humans
was shown to cause severe hypoglycemia, weight gain,
and somatic overgrowth,22 which is the opposite pheno-
type to SHORT syndrome. To assess the impact of PIK3R1
mutations, we evaluated the effects of short-term insulin
stimulation on proximal (i.e., AKT, also known as protein
kinase B) and distal (i.e., glycogen synthesis and glucose
transport) PI3K-dependent insulin signaling in fibroblast
cells derived from two individuals (P1 and P2) with
PIK3R1 mutations and two unaffected males. Skin fibro-
blasts were prepared according to standard procedures, as146 The American Journal of Human Genetics 93, 141–149, July 11, 2described previously.23 Protein levels of PIK3R1 were
evaluated by immunoblot on whole-cell lysates with
antibodies to the p85a subunit (sc-423 [Z-8], Santa Cruz
Biotechnology). Serum-depleted cells were incubated
for 10 (for AKT detection) or 30 min (for the glycogen
synthesis and the glucose-transport assays) with or
without insulin (100 nMole/l). Insulin stimulation was
evaluated by immunoblot analysis on whole-cell lysates
with antibodies to AKT and phospho-AKT-ser473 (SC
8312 and SC 7985, Santa Cruz Biotechnology). Glycogen
synthesis was evaluated by the addition of 14C-glucose
(75 kBq/ml, PerkinElmer) to fibroblasts for 2 hr. Radiola-
beled glycogen was then extracted and counted, as
described previously.24 Similarly, glucose uptake was
evaluated with 3H-2-deoxy-D-glucose (PerkinElmer). As
shown in Figure 2, the studied PIK3R1 mutations did
not affect the protein levels of PIK3R1 (Figure 2A). How-
ever, cells from both affected individuals displayed a
markedly decreased effect of insulin on AKT activation,
glycogen synthesis, and glucose uptake (by 70%–90%; Fig-
ures 2B and 2C), thus indicating severe insulin resistance
for both proximal and distal PI3K-dependent signaling.
These results might partly be explained by the increased
levels of basal activity in cells from affected individuals
(3- to 4-fold, 1.5- to 2-fold, and 1- to 2-fold increase for
AKT activity, glycogen synthesis, and glucose uptake,
respectively). This increased basal activity with further
desensitization to insulin action has been described previ-
ously in other states of severe insulin resistance caused by
mutations in INSR.24–26 Although further metabolic inves-
tigations will be needed for precisely deciphering the
underlying signaling defects, our observations are consis-
tent with impaired insulin-stimulated pathways, which
lead to a generalized insulin-resistance syndrome affecting
glucose homeostasis, growth, adipogenesis, and lipogen-
esis (Figure 1, Table 1, and Table S5).013
Figure 2. Cellular Insulin Resistance in
Subjects with PIK3R1 Mutations
(A and B) PIK3R1 levels and short-term
effects of insulin on proximal PI3K-
dependent insulin signaling in fibroblasts
from affected individuals (P1 and P2) and
controls. PIK3R1 levels (A) and the effect
of insulin on AKT activation (B) were
evaluated by immunoblotting on whole-
cell lysates. Intensities were quantified by
densitometry scanning. PIK3R1 levels and
AKT phosphorylation levels were normal-
ized to b-actin and total AKT, respectively.
Representative immunoblots are shown.
The following abbreviation is used:
p-AKT-ser473, phospho-AKT-ser473.
(C) Short-term effects of insulin on distal
PI3K-dependent signaling. The effects of
insulin on glycogen synthesis and glucose
transport were evaluated by the incorpora-
tion of 14C-glucose into glycogen and the
cellular uptake of 3H-2-deoxy-D-glucose,
respectively. In fibroblasts from control
subjects and individuals P1 and P2, basal
glycogen synthesis was 22.3 5 1.6,
54.6 5 6.0, and 52.5 5 0.4 pmoles of
glucose incorporated into glycogen per
mg protein per hour, respectively, and
basal glucose transport was 10.5 5 1.1,
23.2 5 2.4, and 11.4 5 1.5 pmole of
cellular 2-deoxyglucose per mg protein
per min, respectively.
Results are expressed as means 5 SEM.
Asterisks indicate a statistically significant
difference compared to control cells (p <
0.05, Student’s t test).Mice lacking Pik3r1 display enhanced insulin sensitivity
and glucose tolerance,27 whereas p85 overexpression is
associated with insulin resistance in skeletal muscle,28
thus indicating that p85 subunits act as negative regulators
of PI3K signaling downstream of the insulin receptor.
However, the mechanisms underlying negative regulation
of insulin signaling by the PI3K regulatory subunits remain
unclear.15 Two of the mutations identified here are located
in PIK3R1’s inter-Src homology 2 (iSH2) domain (Figure 1J),
which is a major interacting domain with p110 catalytic
subunits. This interaction regulates PI3K activity through
the formation of active and inactive dimers.29 Although
further functional studies will be necessary for elucidating
the exact mechanisms leading to SHORT syndrome, we
can speculate that these mutations might affect the inter-
action between p85 regulatory subunits and p110 catalytic
subunits and thus lead to decreased PI3K activity.
Other clinical SHORT syndrome features, such as bone
demineralization, ovarian cysts, Rieger anomaly, and
teething delay, are consistent with decreased PI3K-AKT
signaling. Indeed, the PI3K-AKT pathway is critical for
bone development, growth, and integrity and is a key regu-
lator of osteoclastic bone resorption.30 Mice lacking both
Akt1 and Akt2 display a severe bone-deficiency phenotype,
and Akt1–/– mice exhibit growth deficiency, along withThe Amimpaired bone growth early in life and mild osteopenia
in adulthood.31 Besides severe diabetes and lipoatrophy,
loss of Akt2was shown to predisposemice to the formation
of ovarian cysts.32 Finally, haploinsufficiency of PITX2,
which is a downstream phosphorylation target of
AKT2,33 causes Axenfeld-Rieger syndrome (MIM 602482),
a condition that has significant clinical overlap with
SHORT syndrome and is characterized by anterior-segment
eye defects and umbilical and teeth anomalies.34
Because individuals with SHORT syndrome are usually
born small for gestational age (SGA), which predisposes
them to permanent short stature,35 two of the subjects re-
ported here (P1 and P2) were being treated by growth
hormone (GH). This treatment was approved in 2001
and 2003 in the United States and Europe, respectively,
for SGA children without catch-up growth after the age
of 4 years. However, GH treatment is known to induce
hyperinsulinemia and to decrease insulin sensitivity; this
phenomenon might aggravate insulin resistance and
accelerate the onset of diabetes in subjects with SHORT
syndrome, particularly during puberty, when insulin resis-
tance is observed in both normal and diabetic children.36
Given the presence of diabetes in all adult PIK3R1-muta-
tion-positive individuals presented here (Table 1), the
well-known association between insulin resistance anderican Journal of Human Genetics 93, 141–149, July 11, 2013 147
PI3K-pathway dysfunction, and the fact that GH-induced
insulin resistance is rapidly reversible upon treatment
cessation,37 GH treatment was ceased in both subjects.
This well illustrates the fact that genetic findings can
have direct implications for care practice by enabling a
more personalized clinical management.
In conclusion, our findings provide important informa-
tion with respect to the function of PIK3R1 in normal
development and its role in human diseases, including
growth delay, Rieger anomaly and other ocular affections,
insulin resistance, diabetes, paucity of fat, and ovarian
cysts. The relatively mild clinical presentation of several
of the subjects reported here suggests that SHORT syn-
drome might be underdiagnosed and that mutations in
PIK3R1might be a rare cause of apparently nonsyndromic
insulin resistance in lean cases.Supplemental Data
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